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Background: Non-alcoholic steatohepatitis (NASH) is associated with hepatic fibrogenesis. Despite well-known
cholesterol-lowering action of statins, their mechanisms against NASH-mediated fibrogenesis remain unclear.
This study aimed at investigating the in vitro and in vivo anti-fibrotic properties of fluvastatin (Flu).
Methods: Palmitate (PA)-induced changes in intracellular hydrogen peroxide levels in primary rat hepatocytes
(PRHs) and human hepatoma cell line (HepG2) were quantified by dichlorofluorescein diacetate (DCF-DA) dye assay,
whereas changes in expressions of NADPH oxidase gp91phox subunit, α-smooth muscle actin (α-SMA), and NFκB
p65 nuclear translocation were quantified with Western blotting. Quantitative real-time polymerase chain reaction
(q-PCR) was used to investigate mRNA expressions of pro-inflammatory genes (ICAM-1, IL-6, TNF-α). Conditioned
medium (CM) from PA-treated PRHs was applied to cultured rat hepatic stellate cell line, HSC-T6, with or without
Flu-pretreatment for 2 h. Pro-fibrogenic gene expressions (COL1, TIMP-1, TGF-β1, α-SMA) and protein expression of
α-SMA were analyzed. In vivo study using choline-deficient L-amino acid defined (CDAA) diet-induced rat NASH
model was performed by randomly assigning Wistar rats (n = 28) to normal controls (n = 4), CDAA diet with vehicles,
and CDAA diet with Flu (5 mg/kg or 10 mg/kg) (n = 8 each) through gavage for 4 or 8 weeks. Livers were harvested
for histological, Western blot (α-SMA), and q-PCR analyses for expressions of pro-inflammatory (IL-6, iNOS, ICAM-1) and
pro-fibrogenic (Col1, α-SMA, TIMP-1) genes.
Results: In vitro, Flu (1–20 μM) inhibited PA-induced free-radical production, gp91phox expression, and NFκB p65
translocation in HepG2 and PRHs, while CM-induced α-SMA protein expression and pro-fibrogenic gene expressions
in HSC-T6 were suppressed in Flu-pretreated cells compared to those without pretreatment. Moreover, α-SMA protein
expression was significantly decreased in HSC-T6 cultured with CM from PA-Flu-treated PRHs compared to those
cultured with CM from PA-treated PRHs. Flu also reduced steatosis and fibrosis scores, α-SMA protein expression,
mRNA expression of pro-inflammatory and pro-fibrogenic genes in livers of CDAA rats.
Conclusions: We demonstrated PA-induced HSC activation through paracrine effect of hepatocyte in vitro that
was significantly suppressed by pre-treating HSC with Flu. In vivo, Flu alleviated steatosis-induced HSC activation
and hepatic fibrogenesis through mitigating inflammation and oxidative stress, suggesting possible therapeutic
role of Flu against NASH.
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Non-alcoholic fatty liver disease (NAFLD) has become a
public health issue because of the ongoing epidemics of
obesity and type 2 diabetes. The spectrum of NAFLD
ranges from simple steatosis to steatohepatitis, liver fibro-
sis, cirrhosis, and eventually hepatocellular carcinoma [1].
According to the “two-hit-hypothesis” of non-alcoholic
steatohepatitis (NASH), hepatic steatosis (“first hit”) is a
prerequisite for the development of subsequent adverse
events (“second hit”) when combined with unfavorable en-
vironmental and genetic factors, leading to inflammatory
liver damage and fibrogenesis in NASH [2]. In humans
with NAFLD, circulating free fatty acids (FFAs) are com-
monly elevated and their plasma levels correlate with dis-
ease severity. Consistently, FFAs have been proposed to
contribute to the development and progression of NAFLD
and NASH [3,4].
NASH is known to be associated with an increased gen-
eration of reactive oxygen species [5] through nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase-medi-
ated pathways that play a crucial role in the development
of hepatic fibrogenesis [6]. On the other hand, nuclear
factor kappa (NFκB) is a dimeric transcription factor
comprised of five family members RelA (p65), RelB, c-Rel,
p50 and p52 and is a critical mediator of inflammatory re-
sponses [7,8]. Recent studies have shown that modulation
of lipid homeostasis and suppression of NFκB activation
counteract the progression of liver injury in experimental
NASH model [9].
Statins are specific inhibitors of 3-hydroxy-3methylglu
taryl coenzyme A (HMG-CoA) reductase, the rate-limiting
enzyme in cholesterol biosynthesis [10]. In addition to their
cholesterol-lowering effects, statins also possess pleiotropic
properties that account for their anti-inflammatory, anti-
proliferative, anti-thrombotic, anti-oxidative, anti-cancer,
and immunomodulatory actions in vitro and in vivo. It has
been shown that statins can reduce liver triglyceride [11]
and ameliorate severe hepatic steatosis [12], thereby im-
proving NASH-related fibrogenesis. Clinically, the thera-
peutic role of statins in the treatment of patients with
NASH is still controversial [13]. Although it has been re-
ported that statins could improve liver steatosis and re-
duce the NAFLD activity score [14], their efficacy against
fibrosis remains unclear. This study, therefore, aimed at
investigating the therapeutic potential of statins against




A human hepatoma cell line, HepG2, was grown in
Dulbecco’s modified Eagle’s medium (DMEM) with 10%
heat-inactivated fetal bovine serum (FBS). Hepatocytes for
primary culture were isolated from male Wistar rats(275–300 g) using a two-stage non-recirculating perfusion
method [15]. Primary rat hepatocytes (PRHs) were col-
lected and cultured in 6-well plates coated with collagen
film (Vitrogen 100; Collagen Corp., Palo Alto, CA).
Conditioned medium (CM) was collected from hepato-
cytes cultured with 0.1% FBS to minimize confounding ef-
fects from factors present in serum [16]. The hepatic
stellate cell (HSC)‐T6 cell line, an immortalized rat cell
line of HSCs from Professor S. L. Friedman of the Mount
Sinai School of Medicine (New York, USA) as a generous
gift, were maintained in DMEM (containing 10% FBS).
Bioassay systems for the HSC‐T6 cell line [17] have been
established in our laboratory [18,19].
Chemicals and antibodies
Sodium palmitate (PA) and bovine serum albumin (BSA)
were purchased from Sigma-Aldrich (St. Louis, MO,
USA). PA stock solution was prepared as previously
described [20]. Briefly, a 100-mM PA stock solution was
prepared in DMSO. A filtered 3% (w/v) FFA-free BSA so-
lution was prepared with ddH2O and maintained at 55°C
in a water bath. Then 10 μM FFA/BSA solution was ob-
tained by complexing the appropriate amount of PA stock
solution with 3% BSA at 55°C for another 30 min. The
above solution was freshly prepared before use. Fluvastatin
(Flu) used in this study (Lescol®, fluvastatin sodium) was
kindly provided by Novartis company. Anti‐α-SMA,
α-tubulin, PCNA, and NFκB (p65) antibodies were pur-
chased from Santa Cruz (Santa Cruz, CA, USA), while
anti-NADPH oxidase gp91phox subunit and β-catenin anti-
bodies were from Millipore (Bedford, MA, USA).
Measurement of reactive oxygen species (ROS) production
Intracellular H2O2 levels were measured by the conversion
of non-fluorescent 2′,7′-dichlorofluorescein diacetate
(DCF-DA) into 2′,7′-dichlorofluorescein (DCF) [15]. Cells
were incubated with 8-μM DCF-DA for 30 min at 37°C
before treatment with PA. The fluorometric analysis was
performed at indicated time points by the excitation and
emission wavelengths at 485 nm and 530 nm, respectively.
Cytotoxicity assay
The assay of the reduction of 3‐ (4,5‐dimethylthiazol‐2‐yl)‐
2,5‐ diphenyltetrazolium bromide (MTT) was used to
evaluate the potential of PA cytotoxicity. PRHs or HepG2
cells were incubated in 24‐well plates (1 × 105 cells/well)
containing DMEM medium with or without different con-
centrations of PA and fluvastatin (Flu) for 24 h. The absorp-
tion intensity at 540 nm was measured by an ELISA reader.
The relative cell viability was determined by the amount of
MTT converted to the insoluble formazan salt. The optical
density of the formazan formed in the control cells was
taken as 100% viability.
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PRHs or HepG2 cells cultured in the presence or ab-
sence of PA or Flu for indicated time points were col-
lected for protein analyses. Expression of NADPH
oxidase (NOX) subunit gp91phox in membrane fractions
was assessed with subcellular fractionation. Cytoplasmic
and nuclear extracts were prepared using a nuclear ex-
traction kit (Chemicon, Temecula, CA) according to the
manufacturer’s instructions and our published methods
[18,19]. HSC-T6 cells were pretreated with or without
Flu (1 and 5 μM) for 2 h before being incubated with a
conditioned medium (CM) collected from PRHs treated
with PA for 24 h to study the protein expression of α‐
SMA. In addition, CM from PRHs treated with or with-
out Flu was also collected and was added to HSC-T6
cells to study the protein expression of α‐SMA. Protein
lysates from total cell, cytoplasm, membrane or nuclear
fraction were separated with SDS-PAGE and transferred
onto Immobilon‐PVDF (Millipore, Bedford, MA, USA).
After 1-h blocking for nonspecific binding, blots were incu-
bated with specific primary antibodies (1:10000 dilution)
against α‐actin (GTX100095, GeneTex), α‐tubulin (sc-8035,
Santa Cruz Biotechnology, Santa Cruz, CA, USA), PCNA
(sc-56, Santa Cruz), NFκB (p65) (MAB3026, Santa Cruz),
gp91phox (07–024, Millipore) or β-catenin (06–734, Millipore).
After 1-h incubation with HRP-conjugated secondary
antibodies (1:2000) (Santa Cruz), immunodetection was
performed by the Luminescence Imaging System (FUJI
las-4000mini, Japan).
Reverse transcription and quantitative polymerase chain
reaction (q-PCR)
Total RNA was extracted from liver tissue, cultured
PRHs, HepG2 or HSC-T6 using the Tri-reagent (Sigma-
Aldrich, St. Louis, MO, USA) according to the protocolTable 1 Primer sequences for quantitative PCR













TNFα CCCAGGGACCTprovided by the manufacturer. One microgram of RNA
was reversely transcribed to cDNA by using RevertAidTM
First Strand cDNA Synthesis kit (Fermentas, Burlington,
CA, USA). The mRNA levels were analyzed in triplicates
with the use of Smart Quant Green Master mix (Protech,
Taiwan) by LightCycler 480 Real-Time PCR System
(Roche, Indianapolis, IN, USA) and normalized to GAPDH
mRNA expression. The sequences of the primers used for
quantitative PCR were listed in Table 1.
Animal model with hepatic steatosis and fibrosis
A variety of animal models for NAFLD/NASH have been
reported to date, including those of genetically predisposed,
diet-induced, and a combination of the two. Choline-
deficient L-amino acid defined (CDAA) diet was chosen in
this study to investigate the anti-fibrotic role of statin. In
this model, due to the lack of oligopeptides consumption,
severe methyl-deficient state develops with concomitant
lowering of antioxidant defenses, contributing to its fibro-
genicity and carcinogenicity [21]. The advantage of choline-
deficient L-amino acid defined (CDAA) diet model is the
rapid hepatic accumulation of lipids and reliable develop-
ment of fibrosis [22].
Adult male Wistar rats (BioLASCO Taiwan), weighing
180–200 g, were randomly divided into four groups. (i) Nor-
mal controls: Rats receiving regular animal chow (n = 8); (ii)
CDAA: Rats receiving CDAA diet (n = 16) (no. 518753,
Dyets) [21]; (iii) CDAA rats receiving Flu 5 mg/kg/day
(n = 16), and (iv) CDAA rats receiving Flu 10 mg/kg/
day (n = 16), each given by daily gavages. Half of the
animals from each group were sacrificed after 4 weeks
of Flu treatment, while the rest were sacrificed after 8
weeks of treatment. The whole liver was taken and the
left lobe was sampled for subsequent experiments. All
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National Yang Ming University (Approval No. 981266) and
National Research Institute of Chinese Medicine (Approval
No.102-350-1), in accordance with the Guide for the Care
and Use of Laboratory Animals (National Academic Press,
USA, 1996). Serum alanine transaminase (ALT) and aspar-
tate transaminase (AST), creatinine (Cr), cholesterol (Cho),
triglyceride (TG), and glucose (Glu) levels were mea-
sured following standard procedures using a colorimetric
analyzer (Dri‐Chem 3000). Serum TNF‐α concentrations
were determined by specific and sensitive enzyme linked
immunoassays (R &D Systems) [23].
Histopathological examination
Formalin-fixed, paraffin-embedded liver sections were
deparaffinized and stained with hematoxylin-eosin and
Sirius red for histological examination and determination
of collagen distribution, respectively [24]. The scoring sys-
tem used in the present study was adapted from that pre-
viously reported by Brunt et al. that histologically assesses
the extent of steatosis, hepatocyte ballooning, inflamma-
tion, and fibrosis [25] as well as the NAFLD activity score
(NAS) designed by the NASH Clinical Research Network
(CRN) based on the summation of the scores of three key
parameters of NASH including steatosis (0–3), lobular in-
flammation (0–3), and ballooning (0–2) with a final score
ranging from 0 to 8 [26]. Besides, fibrosis was staged as:
Stage 0: No fibrosis; Stage 1: Zone 3 perisinusoidal/pericel-
lular fibrosis, focally or extensively present; Stage 2: Zone
3 perisinusoidal/pericellular fibrosis with focal or extensive
periportal fibrosis; Stage 3: Zone 3 perisinusoidal/pericel-
lular fibrosis and portal fibrosis with focal or extensive
bridging fibrosis; Stage 4: Cirrhosis. The scores were given
by a pathologist (Y.‐T. C.) blinded to the rats’ treatment
assignment after examination of three different areas of a
liver section for each rat.
Statistical analysis
Data are expressed as the mean ± SEM. One‐way analysis
of variance (ANOVA) was used for comparison of bio-
chemical and molecular parameters. A non‐parametric
method (the Dunn procedure under the Kruskal–Wallis
test) was used for multiple pairwise comparisons between
groups for analysis of the histological grades of fibrosis.
Statistical significance was accepted at p < 0.05.
Results
Flu attenuates PA-induced oxidative stress, inflammatory
responses, and fibrogenesis
Inhibition of ROS production and NADPH oxidase gp91phox
expression in PA-treated HepG2 and PRHs by Flu
To demonstrate the anti-fibrotic roles of Flu in steatosis-
induced liver fibrosis, the beneficial effects of Flu on lipid-
induced hepatocyte damage were first investigated. PRHs(isolated from Wistar rats) and HepG2 cells were cultured
in the presence of PA, the most abundant free fatty acid in
circulation. Firstly, we demonstrated that PA and Flu treat-
ment did not alter the cell viability of PRHs and HepG2
cells after 24 hours of exposure (Figure 1A). PA treatment
significantly enhanced ROS production in both HepG2
cells and PRHs at 6 hour and 12 hour detected by fluores-
cence DCF-DA dye (Figure 1B and C). PA (200 μM) sig-
nificantly stimulated ROS production, and Flu (1–20 μM)
concentration-dependently reduced PA-induced ROS
production (Figure 1B and C), with higher concentra-
tions achieving significant reduction in PRHs at 12 hour
(Figure 1C). PA (200 μM) also increased gp91phox expres-
sion in HepG2 and PRHs (Figure 1D). By contrast, Flu
(20 μM) reduced gp91phox expression in both cell types,
indicating suppression of ROS generation after Flu treat-
ment (Figure 1D).
Suppression of NFκB p65 nuclear translocation and
pro-inflammatory gene transcripts in PA-treated HepG2
and PRHs by Flu
While PA (200 μM) stimulated NFκB p65 nuclear
translocation in both HepG2 and PRHs (Figure 2A), Flu
(1–20 μM) attenuated NFκB p65 nuclear translocation
in both cell types (Figure 2A). In addition, Flu treat-
ment inhibited the mRNA expression levels of pro-
inflammatory gene transcripts (ICAM-1, IL-6, TNF-α)
in both PA-treated HepG2 cells and PRHs (Figure 2B
and C). Moreover, there were no significant differences
in the expressions of pro-inflammatory gene transcripts
between the control group and the group treated with
Flu alone (Figure 2B and C).
Suppression of α-SMA expression and pro-fibrogenic gene
transcripts in CM or TGF-β1 -treated HSC-T6 cells by Flu
To test if the activation of HSC was induced directly by
PA or indirectly through the paracrine effect of hepato-
cytes, we cultured HSC-T6 cells either (a) in the presence
of conditioned medium (CM) from PA-treated PRHs or
(b) directly with PA. Transforming growth factor (TGF)-
β1 (1 ng/mL) was used as a positive control to stimulate
α-SMA expression and pro-fibrogenic gene transcription
[18]. Figure 3A showed a significant increase of α-SMA
protein expression in HSC-T6 cells incubated with CM
from PA (200 μM)-treated PRHs, whereas PA did not sig-
nificantly induce α-SMA expression in HSC-T6 cells dir-
ectly both at 100 and 200 μM. In addition, mRNA
expressions of TIMP-1 and α-SMA were increased in
HSC-T6 cells incubated with CM from PA-treated PRHs,
whereas there was no significant difference in the expres-
sions of pro-fibrogenic genes when HSC-T6 cells treated
directly with PA (Figure 3B). These results indicate that,
instead of direct activation of HSCs by PA, HSCs were in-
directly activated by PA via PA-elicited paracrine effect of
Figure 1 (See legend on next page.)
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Figure 1 Effects of fluvastatin (Flu) on cell viability, ROS production and NADPH oxidase subunit gp91phox expression in HepG2 cells and
primary rat hepatocytes (PRHs). (A) Effects of Flu on cell viability of HepG2 cells and PRHs at 24 hr after treatment (n = 3). (B) Flu significantly
reduced the reactive oxygen species (ROS) production of PA-treated HepG2 cells and PRHs at 6 hr after treatments. *p < 0.05 and **p < 0.01 vs. control;
#p < 0.05 and ##p < 0.01 vs. PA treatment (n = 3). (C) Flu significantly attenuated the ROS production of PA-treated HepG2 and PRHs at 12 hr after
treatments. *p < 0.05 and **p < 0.01 vs. control; #p < 0.05 and ##p < 0.01 vs. PA treatment (n = 3). (D) Flu significantly decreased the expression
of NADPH oxidase gp91phox in PA-treated HepG2 cells (left panel) and PRHs (right panel). **p < 0.01 vs. control; #p < 0.05 vs. PA treatment (n = 3).
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duced CM- and TGF-β1-induced α-SMA expression in
cultured HSCs (Figure 3C). Additionally, α-SMA protein
expression was also suppressed in HSC-T6 cells incubated
with Flu (5 μM) alone, indicating that Flu can inhibits acti-
vation of HSCs directly. Figure 3D showed a significant in-
crease of mRNA expressions of pro-fibrogenic genes (Col1,
TIMP-1, TGF-β1, and α-SMA) in HSC-T6 cells incubated
with CM and TGF-β1 (1 ng/ml). Flu treatment attenuated
CM-induced mRNA expressions of Col1, TGF-β1 and
α-SMA, and TGF-β1-induced mRNA expressions of Col1
and α-SMA (Figure 3D).
Suppression of α-SMA expression in HSC-T6 cells by CM
from Flu-treated PRHs
To further investigate the effects of Flu on upstream mech-
anism of HSC activation, we stimulated the HSCs with the
CM from PRHs with or without PA treatment, and CM
from PRHs with or without Flu treatment. Figure 3E and F
showed that both α-SMA mRNA and protein expressions
were significantly reduced in HSCs incubated with CM
collected from PA-Flu-treated PRHs compared to those in-
cubated with CM collected from PA-treated PRHs. Fur-
thermore, α-SMA mRNA and protein expressions were
also decreased in HSC-T6 when treated with CM collected
from Flu-treated PRHs compared to those incubated with
CM without Flu treatment (Figure 3E and F). These re-
sults indicate that Flu not only inhibited α-SMA ex-
pression directly in HSC-T6 (Figure 3C), but it also
decreased α-SMA expression in HSC-T6 cells incu-
bated with CM collected from Flu-treated PRHs.
Anti-fibrotic effects of Flu in CDAA rats
Changes in general features, expressions of serum
biomarkers, and histology
To further evaluate the potential anti-fibrotic role of Flu, a
CDAA diet-induced NASH animal model was used. The
effects of Flu on the general features of CDAA rats were
summarized in Table 2. Four-week and 8-week CDAA rats
showed remarkably higher plasma AST (503 ± 89 vs. 96 ±
13 U/mL, p < 0.05; 373 ± 30 vs. 77 ± 4 U/mL, p < 0.01)
and ALT (134 ± 28 vs. 25 ± 2 U/mL, p < 0.05; 161 ± 16 vs.
25 ± 5 U/mL, p < 0.01) levels compared to those in the
normal controls, indicating hepatic injury in the formers
(Table 2). Levels of ALT in CDAA rats after 8-week Flu
treatment were significantly decreased after receivinghigh-dose (i.e., 10 mg/kg/day) Flu compared to those with-
out Flu treatment (84 ± 24 vs. 161 ± 16 U/mL, p < 0.01).
Moreover, as shown in Table 2, Flu treatments (5 mg/kg
and 10 mg/kg/day) for either 4 or 8 weeks significantly at-
tenuated plasma TNF-α level in CDAA rats compared to
that in the untreated CDAA group (4–week: 67 ± 11 pg/
mL and 64 ± 9 pg/mL vs. 109 ± 12 pg/mL for doses of 5
mg/kg and 10 mg/kg/day, respectively, both p < 0.01;
8–week: 30 ± 11 pg/mL vs. 55 ± 22 pg/mL, p < 0.01; 11 ±
3 pg/mL vs. 55 ± 22 pg/mL, p < 0.05 for doses of 5 mg/kg
and 10 mg/kg/day, respectively).
Histological examination of the livers from rats con-
suming CDAA diet for 4 and 8 weeks revealed progres-
sive lipid accumulation, formation of fibrous septa, and
loss of hepatocytes compared with those from normal
controls (Figure 4A). Sirius Red staining of the liver indi-
cated distinct deposits of collagen fibers after 4-week
and 8-week feeding with CDAA diet (Figure 4B). Flu
treatment (5 mg/kg/day and 10 mg/kg/day) attenuated
the deposition of collagen fibers (Figure 4B). Steatosis
scores of the livers from 8-week high-dose Flu-treated
CDAA rats (2.25 ± 1.17) were significantly lower than
that in untreated CDAA rats (3.00 ± 0.00, p < 0.05,
Table 2), whereas there was no notable difference be-
tween CDAA rats receiving 4-week high-dose Flu and
their untreated counterparts. Besides, no significant reduc-
tion in steatosis score was noted between the low-dose Flu
treatment group and the untreated CDAA animals after
either 4-week or 8-week treatment. Treating CDAA an-
imals with either low- or high-dose Flu for 4 weeks sig-
nificantly suppressed the elevations in fibrosis score
compared to that of untreated CDAA rats (both p < 0.01),
whereas the reduction in fibrotic score was significant
only in CDAA rats receiving 8-week-high-dose Flu
treatment (p < 0.05). Furthermore, there were signifi-
cant differences in the degree of fibrosis in rats being
given different dosages at the 4th week but not at 8th
week (Table 2).
Protein expression of α-SMA in the livers of CDAA rats
Figure 5A shows that α-SMA protein expression was in-
creased significantly in the livers of CDAA rats com-
pared with that in the normal controls (p < 0.01).
Treatment with either 5 mg/kg/day or 10 mg/kg/day of
Flu for 4 and 8 weeks markedly reduced α-SMA protein
expression (p < 0.01).
Figure 2 Effects of fluvastatin (Flu) on NFκB p65 nuclear translocation, mRNA expression levels of pro-inflammatory genes in HepG2
cells and primary rat hepatocytes (PRHs). (A) Pre-treatment with Flu for 2 hr reduced the NFκB p65 nuclear translocation in PA-treated HepG2
cells and PRHs at 6 hr after treatment. *p < 0.05 vs. control; #p < 0.05 and ##p < 0.01 vs. PA treatment (n = 3). (B) Flu treatment inhibited the
mRNA expressions of ICAM-1, IL-6 and TNF-α of PA-treated HepG2 cells while there were no significant differences in the expressions of ICAM-1,
IL-6 and TNF-α between the control group and the group treated with Fluvastatin alone. **p < 0.01 vs. control; #p < 0.05 and ##p < 0.01 vs. PA
treatment (n = 3). (C) Flu treatment decreased the mRNA expressions of ICAM-1, IL-6 and TNF-α of PA-treated PRHs, but no significant differences
in the expressions of these markers between the control group and the group treated with Fluvastatin alone were noted. **p < 0.01 vs. control;
#p < 0.05 and ##p < 0.01 vs. PA treatment (n = 3).
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Figure 3 Effects of fluvastatin (Flu) on α-SMA protein expression and pro-fibrogenic gene transcripts in conditioned medium (CM) or
TGF-β1-treated HSC-T6 cells. (A) HSC-T6 cells incubated in the conditioned medium (CM) from PA-treated PRHs showed significantly increased
α-SMA protein expression, while α-SMA protein expression was not up-regulated in HSC-T6 cells treated directly with PA. TGF-β1 (1 ng/mL)
was used as a positive control *p < 0.05 vs. control. (B) mRNA expressions of TIMP-1 and α-SMA were increased in HSC-T6 cells incubated with
CM, whereas there were no significant differences in the expressions of pro-fibrogenic genes when HSC-T6 cells were treated with PA directly.
TGF-β1 (1 ng/mL) was used as a positive control. **p < 0.01 vs. control. (C) Treatment with Flu significantly reduced CM- and TGF-β1-induced
α-SMA protein expression. Besides, α-SMA protein expression was also suppressed in HSC-T6 cells incubated with Flu (5 μM) alone. *p < 0.05
vs. control; **p < 0.01 vs. control; ##p < 0.01 vs. CM treatment; &&p < 0.01 vs. TGF-β1 treatment. (D) Flu treatment attenuated CM-induced
mRNA expressions of Col1, TGF-β1 and α-SMA, and TGF-β1-induced mRNA expressions of Col1 and α-SMA. **p < 0.01 vs. control; #p < 0.05 vs.
CM treatment; ##p < 0.01 vs. CM treatment; &p < 0.05 vs. TGF-β1 treatment. (E & F) α-SMA protein and mRNA expressions were significantly
decreased in HSC-T6 cells incubated with CM collected from PA-Flu-treated PRHs compared to those incubated with CM collected from
PA-treated PRHs. Furthermore, α-SMA protein and mRNA expressions were also reduced in HSC-T6 cells when treated with CM collected from
Flu-treated PRHs compared to those incubated with CM without Flu treatment. **p < 0.01 vs. control; #p < 0.05 vs. CM (PA 200 μM) treatment;
&p < 0.05 vs. CM without Flu treatment. n=3 for all experiments.
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α-SMA, TIMP-1) and pro-inflammatory genes (IL6, iNOS and
ICAM-1) in CDAA rats
There were significant increases in hepatic mRNA expres-
sions of pro-fibrogenic and pro-inflammatory genes in CDAArats compared to those in normal controls after both 4-week
and 8-week treatments (Figures 5B and 6). Additionally, Flu
treatment attenuated the mRNA expressions of Collagen 1,
α-SMA, TIMP-1, IL-6, iNOS, and ICAM-1 in the 4-week
and 8-week Flu-treated CDAA rats (Figures 5B and 6).
Table 2 General features and serum biochemical analyses in rats fed with choline-deficient L-amino acid defined (CDAA) diet receiving fluvastatin (Flu) or vehicle
treatment compared with normal controls
Groups 4 wk 8 wk








Numbers 4 8 8 8 4 8 8 8
Steatosis score 0.00 ± 0.00 3.00 ± 0.00 ** 3.00 ± 0.00 ** 2.70 ± 0.95 ** 0.00 ± 0.00 3.00 ± 0.00 ** 3.00 ± 0.00 ** 2.25 ± 1.17 #
Hepatocyte ballooning 0.0 ± 0.0 2.0 ± 0.0 ** 2.0 ± 0.0 ** 2.0 ± 0.0 ** 0.0 ± 0.0 2.0 ± 0.0 ** 2.0 ± 0.0 ** 1.5 ± 0.8 **
Inflammation 0.00 ± 0.00 0.60 ± 0.52 0.80 ± 0.42 ** 0.40 ± 0.52 0.00 ± 0.00 1.17 ± 0.25 ** 1.60 ± 0.39 ** 1.0 ± 0.55 **,†
Fibrosis score 0.00 ± 0.00 1.80 ± 0.42 ** 1.20 ± 0.42 # # 0.70 ± 0.48# #, † 0.00 ± 0.00 1.67 ± 0.56 ** 1.15 ± 0.63 ** 0.58 ± 0.92 #
BW (g) 312 ± 7 245 ± 9 ** 217 ± 6 ** 195 ± 8 ** ## 467 ± 10 442 ± 12 419 ± 7 ** 399 ± 7 ** #
LW (g) 10.9 ± 0.4 18.1 ± 0.9 ** 14.7 ± 0.9 ** # 14.3 ± 0.4 ** ## 14.3 ± 0.6 23.5 ± 0.9 ** 20.3 ± 0.7 ** 18.2 ± 1.8 ##
AST (U/L) 96 ± 13 503 ± 89 * 439 ± 90 * 366 ± 72 77 ± 4 373 ± 30 ** 311 ± 26 ** 267 ± 49 **
ALT (U/L) 25 ± 2 134 ± 28 * 160 ± 25 ** 121 ± 20 25 ± 5 161 ± 16 ** 125 ± 11 ** 84 ± 24 ##
Cr (mg/dL) 0.43 ± 0.02 0.51 ± 0.05 0.48 ± 0.03 0.47 ± 0.04 0.40 ± 0.00 0.42 ± 0.01 0.44 ± 0.02 0.41 ± 0.01
TG (mg/dL) 47.5 ± 5.3 22.9 ± 1.9 ** 26.4 ± 2.79 ** 29.7 ± 4.7 * 58 ± 9 30 ± 4 * 24 ± 3 * 41 ± 7
Cholesterol (mg/dL) 69.0 ± 4.4 56.4 ± 1.9 56.3 ± 2.3 60.7 ± 4.4 63 ± 6 55 ± 2 57 ± 2 58 ± 4
Glucose (mg/dL) 158 ± 9 124 ± 6 132 ± 11 126 ± 10 134 ± 12 123 ± 5 127 ± 6 132 ± 3
TNFα (pg/mL) 50 ± 4 109 ± 12 ** 67 ± 11 ## 64 ± 9 ## 35 ± 7 55 ± 22 * 30 ± 11 ## 11 ± 3 #
*p < 0.05, **p < 0.01 vs. control group, #p < 0.05, ##p < 0.01 vs. CDAA group, †p < 0.05 vs. CDAA + Flu (5 mg/kg). BW: Body weight, LW: Liver weight, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase,













Figure 4 Histological examination of liver sections.
Representative liver sections were obtained from rats of normal controls
(n = 4), rats fed with CDAA diet with vehicles, and rats fed with CDAA
diet with Flu (5 mg/kg or 10 mg/kg) (n = 8 each). Sections were stained
with (A) Hematoxylin-eosin or (B) Sirius red. Scale bar = 100 μm.
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In the present study, we demonstrated in vitro and in vivo
the anti-fibrotic effects of Flu in steatosis-induced hepato-
cyte damage models. The results of this study showed that
not only could Flu ameliorate PA-induced ROS produc-
tion, NFκB activity, and pro-inflammatory gene expres-
sions (Figures 1 and 2) in PRHs and HepG2 cells, but it
could also reduce α-SMA protein expression and profibro-
genic genes expressions in PA- or TGF-β1-treated HSC-
T6 cells (Figure 3C and D). Furthermore, the results of the
present study revealed suppression of both mRNA and
protein expressions of α-SMA in HSC-T6 incubated with
the CM collected from PA-Flu-treated PRHs or Flu-treated
PRHs compared to those incubated with CM collected
from PA-treated PRHs or CM without Flu treatment
(Figure 3E and F). Consistent in vivo findings are the
demonstration of the anti-fibrotic (Figures 4 and 5) and
anti-inflammatory (Figure 6) effects of Flu in the CDAA
rat model. In addition to supporting the proposal that
Flu could alleviate steatosis-induced hepatic fibrogen-
esis through suppressing inflammation and oxidative
stress, the most striking finding of the present study is the
revelation of the need for paracrine effect of hepatocyte in
the process of PA-elicited HSC activation.
Increased reactive oxygen species (ROS) generation has
been implicated in the progression of chronic liver dis-
eases. NOX, which is membrane-bound enzyme complex
found in the plasma membrane and in the membranes ofphagosomes, is present in a variety of hepatic cells in-
cluding the Kupffer cells, hepatocytes, and HSCs, and
participates in liver inflammation and fibrosis [27,28].
Structurally, NOX contains two membrane-integrated
components, gp91phox and p22phox, and a number of cyto-
solic regulatory proteins (p47phox, p67phox, p40 phox, and
Rac). The pro-fibrotic and pro-inflammatory roles of
gp91phox are illustrated by the result of a previous study
that demonstrated amelioration of hepatic fibrosis through
knocking out gp91phox in mice [29,30] and that of another
study showing inflammation through TNF receptor-1 ex-
pression and NFκB activation elicited by gp91phox induc-
tion [31]. Moreover, attenuating oxidative stress and
decreasing the expression of NF-κB and subsequent pro-
inflammatory cytokines production have been reported to
be associated with the alleviation of CCl4-induced hepatic
fibrogenesis [32]. Our in vitro results demonstrated that
PA induced both gp91phox expression and NFκB p65 nu-
clear translocation in HepG2 and PRHs. The activation of
gp91phox and NFκB, therefore, are possible mechanisms by
which lipid accumulation causes inflammation and fibro-
sis. Furthermore, Flu (1–20 μM) inhibited PA-induced
ROS production, gp91phox expression (Figure 1), and
NFκB p65 nuclear translocation (Figure 2A), suggesting
anti-oxidative, anti-inflammatory, and anti-fibrotic effects
of Flu in PRHs and HepG2 cells.
A number of recent studies have reported that not only
does statin reduce the concentration of circulating low-
density lipoprotein cholesterol, but it also decreases hepatic
lipid deposition in patients with NASH. However, it is still
controversial whether it could suppress hepatic inflamma-
tion and fibrosis. In terms of organs other than the liver,
several studies have previously shown that statin exerts
anti-fibrotic effects on the kidneys, the lungs, and the heart
[33-36]. Regarding fibrogenesis in the liver, compared to
the results of the present investigation, a previous study
showed that simvastatin improves NASH-related fibrosis
by increasing the expression of eNOS, decreasing the ex-
pression of iNOS, and inhibiting the activation of HSC
in vitro [37]. However, that study did not investigate the
role of hepatocyte in the setting of lipidemia. In this aspect,
the present study demonstrated a critical role of hepatocyte
in the process of free fatty acid-induced HSC activation. In
vivo, it has been shown that statin treatment could ameli-
orate the progression of hepatic steatosis, inflammation,
and fibrosis induced by high-fat [37] and CDAA [38] diets,
indicating that statin is protective against the pathogenesis
of NASH. In this study, we consistently demonstrated the
therapeutic effects of Flu on CDAA-induced liver fibrosis
in vivo (Table 2, Figures 4 and 5), and provided the in vitro
effects of Flu on PA-treated hepatocytes and CM-treated
HSCs. Our in vivo results revealed the down-regulation of
the mRNA expression of pro-inflammatory and pro-
fibrogenic genes as well as plasma TNFα level in CDAA
Figure 5 Anti-fibrotic effects of fluvastatin (Flu) on CDAA rats. (A) Representative result showed that Flu treatment reduced the protein
expression of α-SMA in the liver tissues in CDAA rats at 4 and 8 weeks. **p < 0.01 vs. control rat; ##p < 0.01 vs. CDAA rat. (B) Quantitative PCR
analyses for the expressions of Collagen I, α-SMA, and TIMP-1 transcripts in control rats, CDAA rats and CDAA rats receiving Flu (5 or 10 mg/kg/day).
Densities of Collagen I, α-SMA, and TIMP-1 to G3PDH mRNA levels were analyzed by computerized densitometry and are expressed as the indicated
ratios, respectively. Flu treatment attenuated the expressions of these pro-fibrogenic genes. The number of rats in each column was 8. *p <0.05 vs.
control rat; #p < 0.05 vs. CDAA rat.
Figure 6 Anti-inflammatory effects of fluvastatin (Flu) on CDAA
rats. Quantitative PCR analyses for the expressions of IL6, iNOS and
ICAM-1 transcripts in control rats, CDAA rats and CDAA rats receiving
Flu (5 or 10 mg/kg/day). Densities of IL6, iNOS and ICAM-1 to
G3PDH mRNA levels were analyzed by computerized densitometry
and are expressed as the indicated ratios, respectively. Flu treatment
attenuated the expressions of these pro-inflammatory genes. The
number of rats in each column was 8. *p <0.05 and **p <0.01 vs. the
control rat; #p < 0.05 and ##p < 0.01 vs. CDAA rat.
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gesting the anti-inflammatory and anti-fibrotic properties
of Flu in vivo. On the other hand, our in vitro data identi-
fied increased expressions of pro-inflammatory cytokines
(i.e., ICAM-1, IL-6, and TNF-α) in PA-treated hepatocytes,
while Flu treatment inhibited these pro-inflammatory cyto-
kines expressions in PA-treated hepatocytes (Figures 2B,
C). Furthermore, our results also showed that α-SMA pro-
tein expression was significantly suppressed in HSC-T6
cells incubated with CM collected from PA-Flu-treated
PRHs or Flu-treated PRHs compared to those incubated
with CM collected from PA-treated PRHs or CM without
Flu treatment (Figure 3E and F), indicating that Flu may de-
crease the levels of inflammatory cytokines in CM, thereby
attenuating the activation of HSCs. Therefore, our results
demonstrated PA-induced HSC activation through para-
crine effect of hepatocyte in vitro that was significantly sup-
pressed by the treatment of Flu. Accordingly, our results
revealed that Flu could reduce PA-induced ROS produc-
tion, gp91phox expression (Figure 1), NFκB p65 nuclear
translocation (Figure 2A), and pro-inflammatory genes
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Consistently, Flu was found to attenuate CM-induced or
TGF-β1- induced α-SMA protein expression (marker of
HSC activation) and the expressions of pro-fibrogenic
genes in HSC-T6 cells (Figure 3C and D). Taken together,
the in vitro findings suggest dual therapeutic effects of Flu
on both steatotic hepatocyte and HSCs.
The present study has two noteworthy limitations.
Firstly, studies were not performed on animals with
established diet-induced NASH to elucidate the thera-
peutic effects of Flu. Secondly, studies were not per-
formed on animals treated only with Flu and regular diet
to evaluate the direct effects of Flu on normal rats, its
hepatotoxicity and adverse effects. Nevertheless, q-PCR
on the expressions of three inflammation indicators (i.e.,
ICAM1, IL-6, and TNF-α) in HepG2 cells and PRHs
using Flu alone were performed in the present study that
showed no significant differences in the expressions of
these markers between the control group and the group
treated with Flu alone.
Conclusions
In summary, we demonstrated that the anti-fibrotic effects
of Flu on in vitro and in vivo NASH models could be
through its anti-oxidative and anti-inflammatory proper-
ties. In addition to its well-documented lipid-lowering ef-
fects, the results of the present study further support the
role of Flu as a potential anti-fibrosis agent that may be a
promising candidate for NASH therapy.
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